Login to Your Account

CRUK breathes new life into Astrazeneca’s dumped asthma drug

By Nuala Moran
Staff Writer

Friday, January 3, 2014
LONDON – A drug under development for asthma that was dumped by Astrazeneca plc in July 2005 has been revived as a potential treatment for kidney cancer. AZD2908 will now be taken forward by the charity Cancer Research UK (CRUK), which will complete preclinical development of the CCR4 receptor agonist and move it into a 40-patient trial beginning in 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription